SCHEMBL5134947

SCHEMBL5134947

CCCCn1c(CN(Cc2ccc(CO)cc2)CC2CCCCC2)cnc1-c1ccccc1

nearest known ligand 0.39

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.37
HSD11B1 P28845 2/20 0.35
RORC P51449 4/20 0.35
C5AR1 P21730 1/20 0.34
LTB4R2 Q9NPC1 1/20 0.34
PTGES O14684 1/20 0.33
CSF1R P07333 1/20 0.33
KDM4E B2RXH2 1/20 0.33
ALDH1A1 P00352 1/20 0.33
CYP3A4 P08684 1/20 0.33
HPGD P15428 1/20 0.33
HSD17B10 Q99714 1/20 0.33
BCHE P06276 1/20 0.33
AGTR1 P30556 2/20 0.33
ADORA3 P0DMS8 1/20 0.33
ADORA2A P29274 1/20 0.33
ADORA2B P29275 1/20 0.33
ADORA1 P30542 1/20 0.33
PDE4B Q07343 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5072388 0.93 TSHR (0.41) TSHRHSD11B1RORCC5AR1KDM4E
SCHEMBL5212722 0.87 AGTR1 (0.43) RORCPTGESKDM4EALDH1A1AGTR1
SCHEMBL5135367 0.87 C5AR1 (0.35) TSHRC5AR1BCHE
SCHEMBL5071535 0.86 TSHR (0.45) TSHRHSD11B1C5AR1KDM4EHSD17B10
SCHEMBL5212718 0.86 AGTR1 (0.38) TSHRRORCC5AR1LTB4R2PTGES
SCHEMBL5135712 0.85 MEN1 (0.40) TSHRHSD11B1
SCHEMBL5136714 0.85 KAT8 (0.36) C5AR1LTB4R2PTGESBCHEAGTR1
SCHEMBL5135146 0.85 C5AR1 (0.53) TSHRC5AR1ALDH1A1
SCHEMBL5136016 0.85 C5AR1 (0.53) TSHRC5AR1ALDH1A1
SCHEMBL5137532 0.85 TSHR (0.43) TSHRHSD11B1RORCC5AR1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed